论文部分内容阅读
目的:研究前列腺素E1 脂微球载体制剂(LipoPGE1 ,凯时)治疗糖尿病周围神经病变的临床疗效及观察其不良反应。方法:对确诊为糖尿病合并周围神经病变的30例患者,给予LipoPGE1 1 0 μg/d ,共2周。常规治疗组4 0例给予维生素B1 1 0mg、维生素B1 2 0 . 5mg/d。结果:lipoPGEI组总有效率高于常规治疗组,两组间检验差异有统计学意义(P <0 .0 1 )。LipoPGE1 组MCV和SCY与治疗前后比较差异有统计学意义(P <0 . 0 5 ) :常规治疗组MCV和SCV与治疗前后比较差异无统计学意义(P >0 .0 5 )。药物治疗过程中未见明显不良反应。结论:LipoPGE1 是治疗糖尿病周围神经病变有效且安全的药物。
OBJECTIVE: To study the clinical efficacy of LipoPGE1 (LipoPGE1) in the treatment of diabetic peripheral neuropathy and its adverse reactions. Methods: 30 patients diagnosed with diabetic peripheral neuropathy were given LipoPGE1 10 μg / d for 2 weeks. 40 cases of conventional treatment group given vitamin B1 10mg, vitamin B1 20.5mg / d. Results: The total effective rate of lipoPGEI group was higher than that of routine treatment group. The difference between the two groups was statistically significant (P <0.01). The difference of MCV and SCY between the LipoPGE1 group before and after treatment was statistically significant (P <0.05). There was no significant difference between the MCV and SCV in the conventional treatment group before and after treatment (P> 0.05). No obvious adverse reactions during the drug treatment. Conclusion: LipoPGE1 is effective and safe for the treatment of diabetic peripheral neuropathy.